FDA approves milestone biosimilar insulin drug

The US Food and Drug Administration (FDA) has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Pharma company raises pressure with hypotension drug lawsuit

13 October 2022 Nexus raises second complaint against same parties in a month | Ready-to-use drug that can raise the blood pressure of hypotension patients at issue.

Americas

FDA urges USPTO to tackle rising drug costs

14 September 2021 The US Food and Drug Administration has urged the US Patent and Trademark Office (USPTO) to curb drug costs in the wake of President Joe Biden’s plan to promote competition in the pharmaceutical sector.

Americas

Nexus and Nevakar face off over hypotension drug

19 August 2021 Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

FDA approves milestone biosimilar insulin drug

More on this story

Editor's picks

Editor's picks

More features